Sonoma Pharmaceuticals (SNOA) Competitors $4.43 -0.04 (-0.78%) As of 03:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. CASI, DARE, AKTX, TENX, CVKD, ALLR, MIRA, CLSD, XCUR, and NEUPShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include CASI Pharmaceuticals (CASI), Dare Bioscience (DARE), Akari Therapeutics (AKTX), Tenax Therapeutics (TENX), Cadrenal Therapeutics (CVKD), Allarity Therapeutics (ALLR), MIRA Pharmaceuticals (MIRA), Clearside Biomedical (CLSD), Exicure (XCUR), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors CASI Pharmaceuticals Dare Bioscience Akari Therapeutics Tenax Therapeutics Cadrenal Therapeutics Allarity Therapeutics MIRA Pharmaceuticals Clearside Biomedical Exicure Neuphoria Therapeutics Sonoma Pharmaceuticals (NASDAQ:SNOA) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings. Which has better earnings and valuation, SNOA or CASI? Sonoma Pharmaceuticals has higher earnings, but lower revenue than CASI Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$14.29M0.51-$3.46M-$2.46-1.80CASI Pharmaceuticals$31.56M0.82-$39.26M-$2.89-0.73 Which has more risk and volatility, SNOA or CASI? Sonoma Pharmaceuticals has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Does the media refer more to SNOA or CASI? In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 2 mentions for CASI Pharmaceuticals and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.91 beat CASI Pharmaceuticals' score of 0.47 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Sonoma Pharmaceuticals Very Positive CASI Pharmaceuticals Neutral Do analysts recommend SNOA or CASI? CASI Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 90.39%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CASI Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SNOA or CASI more profitable? Sonoma Pharmaceuticals has a net margin of -23.87% compared to CASI Pharmaceuticals' net margin of -148.55%. Sonoma Pharmaceuticals' return on equity of -50.00% beat CASI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-23.87% -50.00% -16.79% CASI Pharmaceuticals -148.55%-972.55%-99.07% Do institutionals & insiders hold more shares of SNOA or CASI? 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 24.6% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummarySonoma Pharmaceuticals and CASI Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.27M$2.83B$5.75B$10.26BDividend YieldN/A57.24%5.72%4.60%P/E Ratio-1.8023.4275.2626.44Price / Sales0.51530.90456.1288.47Price / CashN/A27.5625.8129.91Price / Book1.625.3913.256.27Net Income-$3.46M$32.95M$3.29B$270.47M7 Day Performance-2.95%0.17%0.68%2.74%1 Month Performance-17.10%3.98%4.54%5.95%1 Year Performance26.71%-2.90%73.36%25.97% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.788 of 5 stars$4.44-0.8%N/A+27.7%$7.27M$14.29M-1.80180Positive NewsCASICASI Pharmaceuticals3.7644 of 5 stars$2.32-1.5%$4.00+72.8%-68.2%$28.47M$28.54M-0.80180Gap DownDAREDare Bioscience2.5552 of 5 stars$2.10-1.4%$10.00+376.0%-36.3%$28.44M-$17.70K-0.9930Positive NewsShort Interest ↓AKTXAkari Therapeutics3.7323 of 5 stars$0.85flat$3.30+288.2%-75.8%$27.73MN/A0.009Short Interest ↓TENXTenax Therapeutics2.2571 of 5 stars$6.04flat$18.00+198.0%+60.4%$27.45MN/A-6.549High Trading VolumeCVKDCadrenal Therapeutics3.5144 of 5 stars$13.21-1.2%$32.00+142.3%+28.8%$27.07MN/A-1.494News CoverageShort Interest ↓ALLRAllarity Therapeutics2.2786 of 5 stars$1.83-2.7%$9.00+391.8%-51.3%$26.76MN/A0.0010Short Interest ↑MIRAMIRA Pharmaceuticals3.019 of 5 stars$1.41+2.2%$17.00+1,105.7%+7.4%$26.70MN/A-2.862Short Interest ↓CLSDClearside Biomedical2.3598 of 5 stars$0.340.0%$4.20+1,150.0%-98.3%$26.62M$1.66M-0.9230Stock SplitGap DownXCURExicure1.454 of 5 stars$4.12-4.3%N/A+142.5%$26.01M$500K-1.0650Positive NewsNEUPNeuphoria Therapeutics2.5788 of 5 stars$13.78+6.1%$21.00+52.4%N/A$25.91M$10K0.00N/A Related Companies and Tools Related Companies CASI Pharmaceuticals Competitors Dare Bioscience Competitors Akari Therapeutics Competitors Tenax Therapeutics Competitors Cadrenal Therapeutics Competitors Allarity Therapeutics Competitors MIRA Pharmaceuticals Competitors Clearside Biomedical Competitors Exicure Competitors Neuphoria Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
